![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Daewoong Pharmaceutical plans to expand its presence of a potassium-competitive acid blocker (P-CAB) drug Fexuclue (fexuprazan) in the African pharmaceutical market for gastroesophageal reflux disease (GERD).
Lead Product(s): Fexuprazan
Therapeutic Area: Gastroenterology Product Name: Fexuclue
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Daewoong Pharmaceutical
Deal Size: $20.3 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 26, 2023